Gilead Sciences at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
Gilead Sciences brings 21 presentations to IDWeek 2026 in Washington, and exhibits at Booth 1301, BS 15, BS 23, BS 24. Its program centres on HIV prevention and treatment, especially early real-world uptake, costs and public health effects of long-acting injectable lenacapavir for prevention. It also brings resistance and virology analyses of remdesivir in immunocompromised COVID patients and obeldesivir in adults with RSV.
| Organization | IDWeek 2026 Attendance |
|---|---|
Gilead Sciences Foster City, CA | |
Biopharmaceutical company that has developed medicines for more than 30 years with the aim of a healthier world. | Booth Exhibiting at Booth 1301, BS 15, BS 23, BS 24 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Wed Oct 21 11:00am–12:30pm Advancing a Panviral Approach to HDV, HCV, HBV and HIV Prevention and Treatment: Lunch Symposium- food is provided by IDWeek HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship Talk Wed Oct 21 11:05am–12:30pm Industry Wed Oct 21 7:00pm–9:00pm Voice of the ART (ists): Dinner Symposium- food is provided by IDWeek HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship Industry Thu Oct 22 7:00am–8:00am Advances in HIV Prevention: The Future is Now - Breakfast Symposium- food is provided by IDWeek HIV, sexually transmitted infections and viral hepatitis Industry Thu Oct 22 12:15pm–1:00pm Paired With Intention: Explore the data behind a novel combination in appropriate virologically suppressed PWH HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship Industry Fri Oct 23 7:00am–8:30am Coffee, Croissants and Capsids, Oh My! - Breakfast Symposium: food is provided by IDWeek HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship Poster Fri Oct 23 12:15pm–1:30pm Association between Treatment Persistence and Healthcare Resource Utilization and Costs Among People with HIV Receiving Oral Antiretroviral Therapy Poster Fri Oct 23 12:15pm–1:30pm Changes in Pre‑Exposure Prophylaxis (PrEP) Cost Sharing and HIV Diagnoses Following United States Preventive Services Task Force (USPSTF) and Affordable Care Act (ACA) Coverage Milestones: An Interrupted Time Series Analysis Poster Fri Oct 23 12:15pm–1:30pm Community HERO Treatment Survey: Characterizing Treatment Journey for Older Persons With HIV Poster Fri Oct 23 12:15pm–1:30pm Descriptive Evaluation of a Medical Affairs–Led Educational Resource to Support Healthcare Providers in the Implementation of Lenacapavir for HIV PrEP Poster Fri Oct 23 12:15pm–1:30pm Evaluating the National- and State-Level Economic and Public Health Effect of Introduction of a Twice-Yearly Injectable PrEP Coupled With Minimal Overall PrEP Expansion in the General US Population and MSM Poster Fri Oct 23 12:15pm–1:30pm Incidence of resistance-associated mutations among people with HIV receiving bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based regimens Industry Fri Oct 23 12:15pm–1:00pm Learn About a PrEP Injectable Option HIV, sexually transmitted infections and viral hepatitis Poster Fri Oct 23 12:15pm–1:30pm Pharmacokinetic and clinical data supporting the lenacapavir (LEN) reloading strategy for bictegravir/lenacapavir (BIC/LEN) single-tablet regimen dosing in the ARTISTRY studies Poster Fri Oct 23 12:15pm–1:30pm Pre-Exposure Prophylaxis (PrEP) Uptake and Care in Locations of High HIV Incidence for Black Cisgender Women (CGW) in the US, 2024 Poster Fri Oct 23 12:15pm–1:30pm Routine HIV Screening to Prevention Services: Diversifying Linkage to HIV Prevention Services across 98 Emergency Departments, Community Health Centers, and High Impact Settings Talk Sat Oct 24 10:30am–10:42am Early Real-World Adoption Patterns of Long-Acting Lenacapavir for HIV PrEP in the United States (June 2025–March 2026) HIV, sexually transmitted infections and viral hepatitis Poster Sat Oct 24 12:15pm–1:30pm Resistance Analysis of Emergent Nsp12 Substitutions Observed in Immunocompromised COVID-19 Patients Treated with Remdesivir Poster Sat Oct 24 12:15pm–1:30pm Virology Analyses from the Obeldesivir Phase 2 Study in Nonhospitalized Adults with Acute Respiratory Syncytial Virus (RSV) Infection Talk Sat Oct 24 12:25pm–12:30pm Changes in Pre‑Exposure Prophylaxis (PrEP) Cost Sharing and HIV Diagnoses Following United States Preventive Services Task Force (USPSTF) and Affordable Care Act (ACA) Coverage Milestones: An Interrupted Time Series Analysis HIV, sexually transmitted infections and viral hepatitis Talk Sat Oct 24 12:30pm–12:35pm Routine HIV Screening to Prevention Services: Diversifying Linkage to HIV Prevention Services across 98 Emergency Departments, Community Health Centers, and High Impact Settings HIV, sexually transmitted infections and viral hepatitisDiagnostics and diagnostic stewardship |
Instantly find 20 buyers from Gilead Sciences
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction